GENOSYL DS for Acute Care

About Vero Biotech

VERO Biotech is a private, commercial-stage biotech company based in Atlanta, Georgia, founded in 2016. The company has developed and gained FDA approval for its GENOSYL® Delivery System, a novel, tankless inhaled nitric oxide delivery device approved for use across all areas of care, including acute care, anesthesia, MRI, and inter-hospital transport. Backed by significant venture funding and recognized with industry awards, VERO is focused on commercializing its platform to address unmet needs in critical care. The company operates with a direct commercialization and support model, reinforced by its Partnership365™ service program.

Therapeutic Areas